United Therapeutics Q1 Revenue Misses Estimates, Declines 2%
UTHR has more than doubled off its 52-week low of $272.12.
Summary
United Therapeutics reported Q1 revenue of $781.50 million, a 2% year-over-year decline, falling short of analyst estimates of $796.92 million. Net income also decreased by 15% year-over-year to $274.90 million. This revenue miss was primarily attributed to lower Nebulized Tyvaso sales, partially offset by growth in Tyvaso DPI. While the company's 10-Q filing on the same day broadly announced Q1 results and highlighted a $1.5 billion accelerated share repurchase and Phase 3 pipeline successes, this news provides the critical financial details of the revenue miss and decline. A revenue miss and decline for a company of this size is a significant negative indicator that could pressure the stock. Investors will be closely watching for the company's ability to achieve sequential quarterly revenue growth and further developments in its pulmonary hypertension and fibrosis pipeline.
At the time of this announcement, UTHR was trading at $556.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.1B. The 52-week trading range was $272.12 to $607.89. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.